medigraphic.com
Asociación Mexicana de Gastroenterología

2007, Number 1

<< Back Next >>

Rev Gastroenterol Mex 2007; 72 (1)

The use of coxibs in the prevention of colorectal adenomas. Is the remedy worse than the disease?
A randomized trial os rofecoxib for the chemoprevention of colorectal adenomas

Ballesteros AMA

Language: Spanish
References: 5
Page: 74
PDF size: 62.62 Kb.


Text Extraction

No abstract


REFERENCES

  1. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-16.

  2. Bresalier RS, Sandler RS, Baron JA, et al Adenomatous polyp prevention on Vioxx trial I. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.

  3. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296: 1619-32.

  4. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-95.

  5. Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 2006; 355: 950-2.




2020     |     www.medigraphic.com